Found 77 matching trials
Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)
PHASE2In advanced metastatic castration resistant prostate cancer (mCRPC) progres...
Location
UCLA / Jonsson Comprehensive Cancer Center
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan
PHASE2The purpose of this study is to assess the efficacy, tolerability, safety, ...
Location
Novartis Investigative Site
177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer
PHASE1This phase I trial compares the effect of lutetium Lu 177 (177\^Lu)-prostat...
Location
City of Hope Medical Center
Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
PHASE2This phase II trial studies how to improve the usage of Lu 177 vipivotide t...
Location
Mayo Clinic in Rochester
177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer
PHASE1This is an open label, single arm, phase 1b study to determine the safety o...
Location
University of California, San Francisco
Pluvicto Real-world Investigation in Survival in Metastatic CRPC
N/AThis study aims to evaluate the various aspects of treatment effectiveness ...
Location
Multiple Locations
Post Marketing Study on Pluvicto in Korea
N/APost marketing study on Pluvicto in Korea...
Location
Novartis Investigative Site
STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer
PHASE1The goal of this clinical trial is to is to investigate if it is possible t...
Location
University Hospitals Cleveland Medical Center Seidman Cancer Center, Case Comprehensive Cancer Center
Escalating Cycle 1 Dose of Lu-177-PSMA-617 for the Treatment of Metastatic Castration Resistant Prostate Cancer
PHASE1This phase I trial studies the safety, side effects, and treatment cycle 1 ...
Location
University of Michigan Rogel Cancer Center
Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
PHASE2This is a single-center, open-label, study of Prostate-Specific Membrane An...
Location
University of California, San Francisco